Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis

ObjectivesPatients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 76; no. 4; pp. 654 - 660
Main Authors Low, Audrey S L, Symmons, Deborah P M, Lunt, Mark, Mercer, Louise K, Gale, Chris P, Watson, Kath D, Dixon, William G, Hyrich, Kimme L
Format Journal Article
LanguageEnglish
Published United States Elsevier Limited 01.04.2017
BMJ Publishing Group
SeriesExtended report
Subjects
Adalimumab - therapeutic use
Adult
Aged
Angina pectoris
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Clinical and Epidemiological Research
Consent
Disease
Etanercept - therapeutic use
Female
Heart attacks
Humans
Incidence
Infliximab - therapeutic use
Male
Middle Aged
Mortality
Myocardial Infarction - epidemiology
Myocardial Infarction - mortality
Patients
Questionnaires
Rheumatoid arthritis
Rheumatology
Severity of Illness Index
Society
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
United Kingdom - epidemiology
United Kingdom > UK
Cardiovascular Disease
Anti-TNF
Rheumatoid Arthritis
Epidemiology
Online AccessGet full text

Cover

Abstract ObjectivesPatients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs).MethodsThis analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression.Results252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups.ConclusionsPatients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
AbstractList Objectives Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). Methods This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression. Results 252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups. Conclusions Patients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
ObjectivesPatients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs).MethodsThis analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naive comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression.Results252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11200 patients receiving TNFi (median follow-up per person 3.5years and 5.3years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups.ConclusionsPatients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression. 252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups. Patients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
ObjectivesPatients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs).MethodsThis analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression.Results252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups.ConclusionsPatients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs).OBJECTIVESPatients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs).This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression.METHODSThis analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression.252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups.RESULTS252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups.Patients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.CONCLUSIONSPatients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
Author Dixon, William G
Hyrich, Kimme L
Symmons, Deborah P M
Low, Audrey S L
Mercer, Louise K
Lunt, Mark
Gale, Chris P
Watson, Kath D
AuthorAffiliation 2 NIHR Manchester Musculoskeletal Biomedical Research Unit , Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK
1 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester , Manchester , UK
4 York Teaching Hospital NHS Foundation Trust , York , UK
3 Division of Epidemiology and Biostatistics , Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds , UK
AuthorAffiliation_xml – name: 1 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester , Manchester , UK
– name: 2 NIHR Manchester Musculoskeletal Biomedical Research Unit , Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK
– name: 3 Division of Epidemiology and Biostatistics , Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds , UK
– name: 4 York Teaching Hospital NHS Foundation Trust , York , UK
Author_xml – sequence: 1
  givenname: Audrey S L
  surname: Low
  fullname: Low, Audrey S L
  email: Kimme.Hyrich@manchester.ac.uk
  organization: Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK
– sequence: 2
  givenname: Deborah P M
  orcidid: 0000-0002-8625-1200
  surname: Symmons
  fullname: Symmons, Deborah P M
  email: Kimme.Hyrich@manchester.ac.uk
  organization: NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
– sequence: 3
  givenname: Mark
  surname: Lunt
  fullname: Lunt, Mark
  email: Kimme.Hyrich@manchester.ac.uk
  organization: Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK
– sequence: 4
  givenname: Louise K
  surname: Mercer
  fullname: Mercer, Louise K
  email: Kimme.Hyrich@manchester.ac.uk
  organization: Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK
– sequence: 5
  givenname: Chris P
  surname: Gale
  fullname: Gale, Chris P
  email: Kimme.Hyrich@manchester.ac.uk
  organization: York Teaching Hospital NHS Foundation Trust, York, UK
– sequence: 6
  givenname: Kath D
  surname: Watson
  fullname: Watson, Kath D
  email: Kimme.Hyrich@manchester.ac.uk
  organization: Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK
– sequence: 7
  givenname: William G
  orcidid: 0000-0001-5881-4857
  surname: Dixon
  fullname: Dixon, William G
  email: Kimme.Hyrich@manchester.ac.uk
  organization: Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK
– sequence: 8
  givenname: Kimme L
  orcidid: 0000-0001-8242-9262
  surname: Hyrich
  fullname: Hyrich, Kimme L
  email: Kimme.Hyrich@manchester.ac.uk
  organization: Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28073800$$D View this record in MEDLINE/PubMed
BookMark eNqNUk2PFCEQJWaN-6F_QUm8eBmFpmnogyZm41eyiYnRM6Gh2mbSDS3Qu87v8Y9Kz6ybdU9zgarivaqi6p2jEx88IPSCkteUsuaN9j4OsEzWpU1FaFOOVsj6ETqjdSOL15ATdEYIYZu6bcQpOk9pW1wiqXyCTitJBJOEnKE_32DU2QWfBjfjDvINgMfwew5piYBzwHmZwhKxBxNDcgn32uQQsfOD69xq5QGinndYe1uixlnwBvZegmuILu9w6PG0C0ZH6_RYQL2OZi1aTDyX8uBzwjcuD3j_K52Ds1jHPBS2S0_R416PCZ7d3hfox8cP3y8_b66-fvpy-f5q0_GK5g2rWmiatullA5a1LYe260Wv26YEuKGaCKCstp3VlEsrLbFGdrUx0HWsBNgFenfIOy_dBNaUrqIe1RzdpONOBe3U_y_eDepnuFacM8LqqiR4dZsghl8LpKwmlwyMo_YQlqSolFRwUVfiCCgXglNSswJ9-QC6LQvxZRJrwqolvOYr6vn95u-6_rfqAhAHwLrHFKG_g1CiVlGpe6JSq6jUQVSF-fYB07i8F02ZghuP4FcHfjdtjy76F8jq7o8
CODEN ARDIAO
CitedBy_id crossref_primary_10_1016_j_monrhu_2022_05_006
crossref_primary_10_1038_s41598_021_99071_9
crossref_primary_10_1038_s41584_023_00969_7
crossref_primary_10_1136_annrheumdis_2021_221996
crossref_primary_10_1182_blood_2019002423
crossref_primary_10_1212_WNL_0000000000007251
crossref_primary_10_5528_wjtm_v8_i1_1
crossref_primary_10_1001_jama_2018_13103
crossref_primary_10_1007_s12688_019_0281_8
crossref_primary_10_1016_j_banm_2020_10_012
crossref_primary_10_2147_JIR_S282691
crossref_primary_10_1007_s00393_018_0584_5
crossref_primary_10_1007_s40744_025_00753_x
crossref_primary_10_3899_jrheum_170202
crossref_primary_10_3899_jrheum_180242
crossref_primary_10_1007_s00281_017_0632_2
crossref_primary_10_1080_14740338_2024_2348575
crossref_primary_10_1093_rheumatology_keab062
crossref_primary_10_1186_s13075_018_1669_x
crossref_primary_10_3389_fcvm_2018_00177
crossref_primary_10_36660_ijcs_20200048
crossref_primary_10_1093_rheumatology_kex434
crossref_primary_10_3310_eme08040
crossref_primary_10_3390_ijms24054606
crossref_primary_10_1111_jdv_19900
crossref_primary_10_1016_j_annder_2024_103287
crossref_primary_10_1093_bioinformatics_btz887
crossref_primary_10_1186_s41927_021_00207_1
crossref_primary_10_3389_fphar_2022_928471
crossref_primary_10_3390_jcm9041227
crossref_primary_10_1016_j_bcp_2019_03_007
crossref_primary_10_1007_s10067_023_06709_2
crossref_primary_10_3899_jrheum_180538
crossref_primary_10_1001_jamadermatol_2020_2977
crossref_primary_10_1186_s42358_021_00186_4
crossref_primary_10_7759_cureus_26430
crossref_primary_10_3390_ijms19071890
crossref_primary_10_21518_2079_701X_2020_11_32_44
crossref_primary_10_1007_s12688_019_0255_x
crossref_primary_10_1016_j_tcm_2023_01_002
crossref_primary_10_1097_MCA_0000000000000899
crossref_primary_10_1159_000540920
crossref_primary_10_1016_S2468_1253_19_30173_6
crossref_primary_10_1080_03009742_2022_2040116
crossref_primary_10_1016_j_semarthrit_2019_07_012
crossref_primary_10_1080_1744666X_2021_1899809
crossref_primary_10_2147_BTT_S364191
crossref_primary_10_1007_s00296_018_4004_6
crossref_primary_10_1016_j_amjms_2022_08_003
crossref_primary_10_1007_s12265_020_09964_9
crossref_primary_10_1080_14740338_2018_1483331
crossref_primary_10_3389_fcvm_2021_658915
crossref_primary_10_1093_rheumatology_kez158
crossref_primary_10_1161_JAHA_123_030387
crossref_primary_10_1093_cvr_cvz042
crossref_primary_10_3390_jcm8040493
crossref_primary_10_1016_j_autrev_2019_05_005
crossref_primary_10_1016_j_rdc_2022_08_005
crossref_primary_10_1177_1759720X241271886
crossref_primary_10_1253_circj_CJ_23_0890
crossref_primary_10_25100_cm_v54i2_5466
crossref_primary_10_1001_jamadermatol_2022_5710
crossref_primary_10_1093_cvr_cvad180
crossref_primary_10_3389_fcvm_2023_1215907
crossref_primary_10_3389_fphar_2018_00055
crossref_primary_10_3390_ijms222413675
crossref_primary_10_3389_fmed_2020_556086
crossref_primary_10_1093_rheumatology_key059
crossref_primary_10_1097_FJC_0000000000000595
crossref_primary_10_1161_JAHA_124_039216
crossref_primary_10_1007_s40744_022_00434_z
crossref_primary_10_1038_s41569_018_0064_2
crossref_primary_10_5114_reum_2019_83236
crossref_primary_10_1177_1759720X221114101
crossref_primary_10_1111_bjd_18245
crossref_primary_10_1016_j_autrev_2019_102398
crossref_primary_10_1007_s00011_018_1139_6
crossref_primary_10_2174_1570161117666190619143842
crossref_primary_10_1007_s00296_022_05136_x
crossref_primary_10_1007_s41970_018_0043_4
crossref_primary_10_3390_life13020319
crossref_primary_10_1093_rheumatology_kead039
crossref_primary_10_1002_acr_23875
crossref_primary_10_1136_rmdopen_2019_001032
crossref_primary_10_1016_j_jtumed_2024_08_001
crossref_primary_10_1016_j_hsr_2023_100108
crossref_primary_10_1093_rheumatology_keaa209
crossref_primary_10_1016_j_jaad_2020_03_033
crossref_primary_10_2174_2772434418666230406083149
crossref_primary_10_1186_s13075_018_1805_7
crossref_primary_10_1007_s12016_018_8714_z
crossref_primary_10_3390_ph15010011
crossref_primary_10_3390_rheumato5010003
crossref_primary_10_1161_CIRCRESAHA_121_319877
crossref_primary_10_3390_diagnostics13091653
crossref_primary_10_2174_1570161119666210129142707
crossref_primary_10_1007_s40259_023_00612_7
crossref_primary_10_1007_s00393_019_0637_4
crossref_primary_10_1097_CM9_0000000000000530
crossref_primary_10_3390_jcm10030509
crossref_primary_10_1136_annrheumdis_2019_216653
crossref_primary_10_1136_rmdopen_2018_000763
crossref_primary_10_1016_j_jbspin_2021_105174
crossref_primary_10_1038_s41413_018_0016_9
crossref_primary_10_1016_j_monrhu_2017_11_002
crossref_primary_10_1371_journal_pone_0221477
crossref_primary_10_2174_1381612825666190830153056
crossref_primary_10_2174_1570161118666200214115532
crossref_primary_10_1136_annrheumdis_2017_211727
crossref_primary_10_1371_journal_pone_0215999
crossref_primary_10_3389_fneur_2023_1197212
crossref_primary_10_1186_s13075_024_03352_3
crossref_primary_10_3390_jcm9103267
crossref_primary_10_1007_s00393_018_0460_3
crossref_primary_10_1016_j_amjms_2023_09_014
crossref_primary_10_1007_s00296_017_3861_8
crossref_primary_10_1177_1759720X231187191
crossref_primary_10_37882_2223_2966_2021_05_34
crossref_primary_10_3389_fcvm_2023_1206541
Cites_doi 10.1136/annrheumdis-2011-200726
10.1093/rheumatology/ken242
10.1002/sim.4314
10.1002/art.24092
10.1002/art.20853
10.1186/ar4584
10.1073/pnas.070036297
10.1136/annrheumdis-2014-206624
10.1002/art.23811
10.1136/annrheumdis-2014-206411
10.3899/jrheum.131464
10.1002/art.22094
10.1038/nature01323
10.1136/hrt.2008.144022
10.1136/annrheumdis-2011-201148
10.1136/heartjnl-2012-302632
10.1016/j.pharmthera.2010.05.002
10.1111/j.1749-6632.2009.05287.x
10.1002/art.22809
10.1016/j.amjmed.2013.02.016
10.1136/annrheumdis-2013-204531
10.1136/bmj.b2393
10.1161/CIRCULATIONAHA.107.187397
10.1002/art.30654
10.1002/art.39098
10.1136/ard.2010.129916
10.1002/acr.22166
10.1136/hrt.2009.192328
10.1093/rheumatology/keq209
10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R
10.1136/ard.2006.063867
10.1002/art.22255
ContentType Journal Article
Contributor Hordon, Lesley
Knight, Susan
Jubb, Ronald
Choy, Ernest
Kitas, George
Clarke, Shane
Hopkinson, Neil
Coulson, Amanda
Scott, David
McCrae, Fiona
Bruce, Ian
Taggart, Allister
Abernethy, Rikki
Maiden, Nicola
Price, Tom
Capell, Hilary
Goodfellow, Rhian
Bukhari, Marwan
Hassell, Andy
Green, Sandra
O'Reilly, Sheila
Porter, Duncan
Thompson, Paul
Sanders, Paul
Harrison, Bev
Benitha, Romela
Griffiths, Ian
Klimiuk, Peter
Walsh, David
Emery, Paul
Contributor_xml – sequence: 1
  givenname: Nicola
  surname: Maiden
  fullname: Maiden, Nicola
– sequence: 2
  givenname: Tom
  surname: Price
  fullname: Price, Tom
– sequence: 3
  givenname: Neil
  surname: Hopkinson
  fullname: Hopkinson, Neil
– sequence: 4
  givenname: Sheila
  surname: O'Reilly
  fullname: O'Reilly, Sheila
– sequence: 5
  givenname: Lesley
  surname: Hordon
  fullname: Hordon, Lesley
– sequence: 6
  givenname: Ian
  surname: Griffiths
  fullname: Griffiths, Ian
– sequence: 7
  givenname: Duncan
  surname: Porter
  fullname: Porter, Duncan
– sequence: 8
  givenname: Hilary
  surname: Capell
  fullname: Capell, Hilary
– sequence: 9
  givenname: Andy
  surname: Hassell
  fullname: Hassell, Andy
– sequence: 10
  givenname: Romela
  surname: Benitha
  fullname: Benitha, Romela
– sequence: 11
  givenname: Ernest
  surname: Choy
  fullname: Choy, Ernest
– sequence: 12
  givenname: David
  surname: Walsh
  fullname: Walsh, David
– sequence: 13
  givenname: Paul
  surname: Emery
  fullname: Emery, Paul
– sequence: 14
  givenname: Susan
  surname: Knight
  fullname: Knight, Susan
– sequence: 15
  givenname: Ian
  surname: Bruce
  fullname: Bruce, Ian
– sequence: 16
  givenname: Allister
  surname: Taggart
  fullname: Taggart, Allister
– sequence: 17
  givenname: David
  surname: Scott
  fullname: Scott, David
– sequence: 18
  givenname: Paul
  surname: Thompson
  fullname: Thompson, Paul
– sequence: 19
  givenname: Fiona
  surname: McCrae
  fullname: McCrae, Fiona
– sequence: 20
  givenname: Rhian
  surname: Goodfellow
  fullname: Goodfellow, Rhian
– sequence: 21
  givenname: George
  surname: Kitas
  fullname: Kitas, George
– sequence: 22
  givenname: Ronald
  surname: Jubb
  fullname: Jubb, Ronald
– sequence: 23
  givenname: Rikki
  surname: Abernethy
  fullname: Abernethy, Rikki
– sequence: 24
  givenname: Shane
  surname: Clarke
  fullname: Clarke, Shane
– sequence: 25
  givenname: Sandra
  surname: Green
  fullname: Green, Sandra
– sequence: 26
  givenname: Paul
  surname: Sanders
  fullname: Sanders, Paul
– sequence: 27
  givenname: Amanda
  surname: Coulson
  fullname: Coulson, Amanda
– sequence: 28
  givenname: Bev
  surname: Harrison
  fullname: Harrison, Bev
– sequence: 29
  givenname: Marwan
  surname: Bukhari
  fullname: Bukhari, Marwan
– sequence: 30
  givenname: Peter
  surname: Klimiuk
  fullname: Klimiuk, Peter
Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Copyright: 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017
Copyright_xml – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
– notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
– notice: Copyright: 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
– notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017
CorporateAuthor British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium
CorporateAuthor_xml – name: British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium
DBID 9YT
ACMMV
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
7T5
H94
5PM
DOI 10.1136/annrheumdis-2016-209784
DatabaseName BMJ Open Access Journals
BMJ Journals:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Database
ProQuest Central
Natural Science Collection
BMJ Journals
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Consumer Health Database (subscription)
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Immunology Abstracts
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList ProQuest Central Student
AIDS and Cancer Research Abstracts
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: ACMMV
  name: BMJ Journals:Open Access
  url: https://journals.bmj.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central (New)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 660
ExternalDocumentID PMC5530342
4321357777
28073800
10_1136_annrheumdis_2016_209784
annrheumdis
Genre Journal Article
Comparative Study
GeographicLocations United Kingdom--UK
GeographicLocations_xml – name: United Kingdom--UK
GrantInformation_xml – fundername: Medical Research Council
  grantid: G0902272
– fundername: ;
  grantid: 20380
– fundername: ;
  grantid: G0701380/1; G0902272
– fundername: ;
  grantid: NIHR-CTF-2014-03-03
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
9YT
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACMMV
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
AAFWJ
AALRI
AAYXX
CITATION
PHGZM
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
3V.
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
7T5
H94
0R~
5PM
ID FETCH-LOGICAL-b521t-329e6696f86ed3995e9bf7fa9686e5c1a07e134dbda158d8d0dc8b4ccebb358d3
IEDL.DBID 9YT
ISSN 0003-4967
1468-2060
IngestDate Thu Aug 21 18:43:01 EDT 2025
Fri Jul 11 07:07:30 EDT 2025
Thu Jul 10 18:58:24 EDT 2025
Fri Jul 25 11:15:09 EDT 2025
Mon Jul 21 06:02:31 EDT 2025
Thu Apr 24 23:03:41 EDT 2025
Tue Jul 01 00:58:25 EDT 2025
Thu Apr 24 23:08:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Cardiovascular Disease
Anti-TNF
Rheumatoid Arthritis
Epidemiology
Language English
License This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b521t-329e6696f86ed3995e9bf7fa9686e5c1a07e134dbda158d8d0dc8b4ccebb358d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
Handling editor Tore K Kvien
ORCID 0000-0001-8242-9262
0000-0001-5881-4857
0000-0002-8625-1200
OpenAccessLink http://dx.doi.org/10.1136/annrheumdis-2016-209784
PMID 28073800
PQID 1882905453
PQPubID 2041045
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5530342
proquest_miscellaneous_1881757427
proquest_miscellaneous_1857751043
proquest_journals_1882905453
pubmed_primary_28073800
crossref_primary_10_1136_annrheumdis_2016_209784
crossref_citationtrail_10_1136_annrheumdis_2016_209784
bmj_primary_10_1136_annrheumdis_2016_209784
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-04-01
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 04
  year: 2017
  text: 2017-04-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Kidlington
– name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationSeriesTitle Extended report
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAlternate Ann Rheum Dis
PublicationYear 2017
Publisher Elsevier Limited
BMJ Publishing Group
Publisher_xml – name: Elsevier Limited
– name: BMJ Publishing Group
References Myasoedova, Chandran, Ilhan 2016; 75
Solomon, Avorn, Katz 2006; 54
Bili, Tang, Pranesh 2014; 66
van Buuren, Boshuizen, Knook 1999; 18
Simms, Reynolds, Pieper 2013; 99
Libby 2002; 420
Ljung, Simard, Jacobsson 2012; 64
Dixon, Symmons 2007; 66
Gonzalez-Gay, Gonzalez-Juanatey, Vazquez-Rodriguez 2010; 1193
2007
Daïen, Duny, Barnetche 2012; 71
Dixon, Watson, Lunt 2007; 56
Hyrich, Watson, Isenberg 2008; 47
Gale, Manda, Weston 2009; 95
Greenberg, Kremer, Curtis 2011; 70
Arts, Fransen, den Broeder 2015; 74
Aviña-Zubieta, Choi, Sadatsafavi 2008; 59
Avina-Zubieta, Thomas, Sadatsafavi 2012; 71
Suissa, Bernatsky, Hudson 2006; 55
Roubille, Richer, Starnino 2015; 74
Sterne, White, Carlin 2009; 338
Kurrelmeyer, Michael, Baumgarten 2000; 97
Herrett, Smeeth, Walker 2010; 96
Thygesen, Alpert, White 2007; 116
Ljung, Askling, Rantapää-Dahlqvist 2014; 16
Hyrich, Watson, Lunt 2011; 50
Cattle, Baxter, Greenwood 2011; 30
Solomon, Curtis, Saag 2013; 126
Kleinbongard, Heusch, Schulz 2010; 127
Desai, Rao, Hansen 2014; 41
Wolfe, Michaud 2008; 58
Maradit-Kremers, Crowson, Nicola 2005; 52
Solomon, Reed, Kremer 2015; 67
Dixon (10.1136/annrheumdis-2016-209784_bib7) 2007; 56
Roubille (10.1136/annrheumdis-2016-209784_bib15) 2015; 74
Avina-Zubieta (10.1136/annrheumdis-2016-209784_bib2) 2012; 71
Ljung (10.1136/annrheumdis-2016-209784_bib8) 2012; 64
Gale (10.1136/annrheumdis-2016-209784_bib26) 2009; 95
Ljung (10.1136/annrheumdis-2016-209784_bib29) 2014; 16
Aviña-Zubieta (10.1136/annrheumdis-2016-209784_bib1) 2008; 59
Sterne (10.1136/annrheumdis-2016-209784_bib25) 2009; 338
Simms (10.1136/annrheumdis-2016-209784_bib27) 2013; 99
Solomon (10.1136/annrheumdis-2016-209784_bib33) 2015; 67
Dixon (10.1136/annrheumdis-2016-209784_bib16) 2007; 66
Hyrich (10.1136/annrheumdis-2016-209784_bib19) 2008; 47
Herrett (10.1136/annrheumdis-2016-209784_bib21) 2010; 96
Kleinbongard (10.1136/annrheumdis-2016-209784_bib18) 2010; 127
Bili (10.1136/annrheumdis-2016-209784_bib13) 2014; 66
10.1136/annrheumdis-2016-209784_bib20
Arts (10.1136/annrheumdis-2016-209784_bib5) 2015; 74
Libby (10.1136/annrheumdis-2016-209784_bib30) 2002; 420
Desai (10.1136/annrheumdis-2016-209784_bib14) 2014; 41
Maradit-Kremers (10.1136/annrheumdis-2016-209784_bib3) 2005; 52
Solomon (10.1136/annrheumdis-2016-209784_bib10) 2013; 126
Wolfe (10.1136/annrheumdis-2016-209784_bib12) 2008; 58
Cattle (10.1136/annrheumdis-2016-209784_bib28) 2011; 30
Solomon (10.1136/annrheumdis-2016-209784_bib9) 2006; 54
Daïen (10.1136/annrheumdis-2016-209784_bib31) 2012; 71
Gonzalez-Gay (10.1136/annrheumdis-2016-209784_bib32) 2010; 1193
van Buuren (10.1136/annrheumdis-2016-209784_bib24) 1999; 18
Myasoedova (10.1136/annrheumdis-2016-209784_bib4) 2016; 75
Thygesen (10.1136/annrheumdis-2016-209784_bib22) 2007; 116
Kurrelmeyer (10.1136/annrheumdis-2016-209784_bib17) 2000; 97
Hyrich (10.1136/annrheumdis-2016-209784_bib23) 2011; 50
Greenberg (10.1136/annrheumdis-2016-209784_bib6) 2011; 70
Suissa (10.1136/annrheumdis-2016-209784_bib11) 2006; 55
References_xml – volume: 66
  start-page: 1132
  year: 2007
  article-title: What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology
  publication-title: Ann Rheum Dis
– volume: 71
  start-page: 1524
  year: 2012
  article-title: Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200726
– volume: 47
  start-page: 1441
  year: 2008
  article-title: The British Society for Rheumatology Biologics Register: 6 years on
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/ken242
– volume: 30
  start-page: 2736
  year: 2011
  article-title: Multiple imputation for completion of a national clinical audit dataset
  publication-title: Stat Med
  doi: 10.1002/sim.4314
– volume: 59
  start-page: 1690
  year: 2008
  article-title: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies
  publication-title: Arthritis Care Res
  doi: 10.1002/art.24092
– volume: 52
  start-page: 402
  year: 2005
  article-title: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study
  publication-title: Arthritis Rheum
  doi: 10.1002/art.20853
– volume: 16
  start-page: R127
  year: 2014
  article-title: The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4584
– volume: 18
  start-page: 681
  year: 1999
  article-title: Multiple imputation of missing blood pressure covariates in survival analysis
  publication-title: Stat Med
– volume: 54
  start-page: 3790
  year: 2006
  article-title: Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
  publication-title: Arthritis Rheum
– volume: 97
  start-page: 5456
  year: 2000
  article-title: Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.070036297
– year: 2007
  article-title: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
– volume: 74
  start-page: 480
  year: 2015
  article-title: The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2014-206624
– volume: 58
  start-page: 2612
  year: 2008
  article-title: The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.23811
– volume: 75
  start-page: 560
  year: 2016
  article-title: The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2014-206411
– volume: 41
  start-page: 2129
  year: 2014
  article-title: Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.131464
– volume: 55
  start-page: 531
  year: 2006
  article-title: Antirheumatic drug use and the risk of acute myocardial infarction
  publication-title: Arthritis Care Res
  doi: 10.1002/art.22094
– volume: 420
  start-page: 868
  year: 2002
  article-title: Inflammation in atherosclerosis
  publication-title: Nature
  doi: 10.1038/nature01323
– volume: 95
  start-page: 221
  year: 2009
  article-title: Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database
  publication-title: Heart
  doi: 10.1136/hrt.2008.144022
– volume: 71
  start-page: 862
  year: 2012
  article-title: Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: A systematic review with meta-analysis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-201148
– volume: 99
  start-page: 35
  year: 2013
  article-title: Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003–2009: National Institute for Cardiovascular Outcomes Research (NICOR)
  publication-title: Heart
  doi: 10.1136/heartjnl-2012-302632
– volume: 127
  start-page: 295
  year: 2010
  article-title: TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2010.05.002
– volume: 1193
  start-page: 153
  year: 2010
  article-title: Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.2009.05287.x
– volume: 56
  start-page: 2905
  year: 2007
  article-title: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22809
– volume: 126
  start-page: 730.e9
  year: 2013
  article-title: Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2013.02.016
– volume: 74
  start-page: 998
  year: 2015
  article-title: The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204531
– volume: 338
  start-page: b2393
  year: 2009
  article-title: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls
  publication-title: BMJ
  doi: 10.1136/bmj.b2393
– volume: 116
  start-page: 2634
  year: 2007
  article-title: Universal definition of myocardial infarction
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.107.187397
– volume: 64
  start-page: 42
  year: 2012
  article-title: Treatment with tumour necrosis factor-inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.30654
– volume: 67
  start-page: 1449
  year: 2015
  article-title: Disease activity in rheumatoid arthritis and the risk of cardiovascular events
  publication-title: Ann N Y Acad Sci
  doi: 10.1002/art.39098
– volume: 70
  start-page: 576
  year: 2011
  article-title: Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.129916
– volume: 66
  start-page: 355
  year: 2014
  article-title: Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis
  publication-title: Arthritis Care Res
  doi: 10.1002/acr.22166
– volume: 96
  start-page: 1264
  year: 2010
  article-title: The Myocardial Ischaemia National Audit Project (MINAP)
  publication-title: Heart
  doi: 10.1136/hrt.2009.192328
– volume: 50
  start-page: 117
  year: 2011
  article-title: Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keq209
– volume: 126
  start-page: 7309
  year: 2013
  ident: 10.1136/annrheumdis-2016-209784_bib10
  article-title: Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2013.02.016
– volume: 18
  start-page: 681
  year: 1999
  ident: 10.1136/annrheumdis-2016-209784_bib24
  article-title: Multiple imputation of missing blood pressure covariates in survival analysis
  publication-title: Stat Med
  doi: 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R
– volume: 58
  start-page: 2612
  year: 2008
  ident: 10.1136/annrheumdis-2016-209784_bib12
  article-title: The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.23811
– volume: 70
  start-page: 576
  year: 2011
  ident: 10.1136/annrheumdis-2016-209784_bib6
  article-title: Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.129916
– volume: 64
  start-page: 42
  year: 2012
  ident: 10.1136/annrheumdis-2016-209784_bib8
  article-title: Treatment with tumour necrosis factor-inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.30654
– volume: 74
  start-page: 480
  year: 2015
  ident: 10.1136/annrheumdis-2016-209784_bib15
  article-title: The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2014-206624
– volume: 66
  start-page: 1132
  year: 2007
  ident: 10.1136/annrheumdis-2016-209784_bib16
  article-title: What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.063867
– volume: 30
  start-page: 2736
  year: 2011
  ident: 10.1136/annrheumdis-2016-209784_bib28
  article-title: Multiple imputation for completion of a national clinical audit dataset
  publication-title: Stat Med
  doi: 10.1002/sim.4314
– volume: 71
  start-page: 862
  year: 2012
  ident: 10.1136/annrheumdis-2016-209784_bib31
  article-title: Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: A systematic review with meta-analysis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-201148
– volume: 56
  start-page: 2905
  year: 2007
  ident: 10.1136/annrheumdis-2016-209784_bib7
  article-title: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22809
– volume: 99
  start-page: 35
  year: 2013
  ident: 10.1136/annrheumdis-2016-209784_bib27
  article-title: Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003–2009: National Institute for Cardiovascular Outcomes Research (NICOR)
  publication-title: Heart
  doi: 10.1136/heartjnl-2012-302632
– volume: 50
  start-page: 117
  year: 2011
  ident: 10.1136/annrheumdis-2016-209784_bib23
  article-title: Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keq209
– ident: 10.1136/annrheumdis-2016-209784_bib20
– volume: 59
  start-page: 1690
  year: 2008
  ident: 10.1136/annrheumdis-2016-209784_bib1
  article-title: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies
  publication-title: Arthritis Care Res
  doi: 10.1002/art.24092
– volume: 16
  start-page: R127
  year: 2014
  ident: 10.1136/annrheumdis-2016-209784_bib29
  article-title: The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4584
– volume: 52
  start-page: 402
  year: 2005
  ident: 10.1136/annrheumdis-2016-209784_bib3
  article-title: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study
  publication-title: Arthritis Rheum
  doi: 10.1002/art.20853
– volume: 338
  start-page: b2393
  year: 2009
  ident: 10.1136/annrheumdis-2016-209784_bib25
  article-title: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls
  publication-title: BMJ
  doi: 10.1136/bmj.b2393
– volume: 47
  start-page: 1441
  year: 2008
  ident: 10.1136/annrheumdis-2016-209784_bib19
  article-title: The British Society for Rheumatology Biologics Register: 6 years on
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/ken242
– volume: 71
  start-page: 1524
  year: 2012
  ident: 10.1136/annrheumdis-2016-209784_bib2
  article-title: Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200726
– volume: 55
  start-page: 531
  year: 2006
  ident: 10.1136/annrheumdis-2016-209784_bib11
  article-title: Antirheumatic drug use and the risk of acute myocardial infarction
  publication-title: Arthritis Care Res
  doi: 10.1002/art.22094
– volume: 1193
  start-page: 153
  year: 2010
  ident: 10.1136/annrheumdis-2016-209784_bib32
  article-title: Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.2009.05287.x
– volume: 97
  start-page: 5456
  year: 2000
  ident: 10.1136/annrheumdis-2016-209784_bib17
  article-title: Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.070036297
– volume: 54
  start-page: 3790
  year: 2006
  ident: 10.1136/annrheumdis-2016-209784_bib9
  article-title: Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22255
– volume: 116
  start-page: 2634
  year: 2007
  ident: 10.1136/annrheumdis-2016-209784_bib22
  article-title: Universal definition of myocardial infarction
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.107.187397
– volume: 66
  start-page: 355
  year: 2014
  ident: 10.1136/annrheumdis-2016-209784_bib13
  article-title: Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis
  publication-title: Arthritis Care Res
  doi: 10.1002/acr.22166
– volume: 96
  start-page: 1264
  year: 2010
  ident: 10.1136/annrheumdis-2016-209784_bib21
  article-title: The Myocardial Ischaemia National Audit Project (MINAP)
  publication-title: Heart
  doi: 10.1136/hrt.2009.192328
– volume: 41
  start-page: 2129
  year: 2014
  ident: 10.1136/annrheumdis-2016-209784_bib14
  article-title: Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.131464
– volume: 95
  start-page: 221
  year: 2009
  ident: 10.1136/annrheumdis-2016-209784_bib26
  article-title: Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database
  publication-title: Heart
  doi: 10.1136/hrt.2008.144022
– volume: 127
  start-page: 295
  year: 2010
  ident: 10.1136/annrheumdis-2016-209784_bib18
  article-title: TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2010.05.002
– volume: 420
  start-page: 868
  year: 2002
  ident: 10.1136/annrheumdis-2016-209784_bib30
  article-title: Inflammation in atherosclerosis
  publication-title: Nature
  doi: 10.1038/nature01323
– volume: 75
  start-page: 560
  year: 2016
  ident: 10.1136/annrheumdis-2016-209784_bib4
  article-title: The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2014-206411
– volume: 67
  start-page: 1449
  year: 2015
  ident: 10.1136/annrheumdis-2016-209784_bib33
  article-title: Disease activity in rheumatoid arthritis and the risk of cardiovascular events
  publication-title: Ann N Y Acad Sci
– volume: 74
  start-page: 998
  year: 2015
  ident: 10.1136/annrheumdis-2016-209784_bib5
  article-title: The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2013-204531
SSID ssj0000818
Score 2.5414102
Snippet ObjectivesPatients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased...
Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven...
Objectives Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased...
SourceID pubmedcentral
proquest
pubmed
crossref
bmj
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 654
SubjectTerms Adalimumab - therapeutic use
Adult
Aged
Angina pectoris
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Clinical and Epidemiological Research
Consent
Disease
Etanercept - therapeutic use
Female
Heart attacks
Humans
Incidence
Infliximab - therapeutic use
Male
Middle Aged
Mortality
Myocardial Infarction - epidemiology
Myocardial Infarction - mortality
Patients
Questionnaires
Rheumatoid arthritis
Rheumatology
Severity of Illness Index
Society
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
United Kingdom - epidemiology
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fi9QwEA56gvginj_r3UkE36S4adIkfTpEPA7hfPJg30rSpLRy2-5td8H7e_xHnUnTnqtw-tY2KQ2dycyXyWQ-Qt4xnjusWpLKOlepyIxOrdMyBWwP_tJ7qRzGOy6-yvNL8WWZL2PAbYhplZNNDIba9RXGyD8wjVt-4O_56fo6RdYo3F2NFBr3yQMsXYYpXWqpbi2xZnpizBOFVDG_i_FA8rJp_G7l2gEUhcHg8ECDAA9jV9_3fdRfwPPP_MnfHNLZE_I4Ikn6cRT9Ibnnu6fk4UXcK39Gfs55bk27pjEfi_of6x6DgnTb0-0O1v0b2nkcRjvQkXuHtl3T2havxsNZN9R0jmJMPvCPhjvwpx5p72hf09UN-EPUsyvoVMPEwY_CJY01WweKwV4afgQs8VtHQV2bUEzpObk8-_zt03kaKRlSi8wHKc8KL2Uhay29w1OxvrC1qk0h4UFeMbNQnnHhrDMs1067hau0FVXlreXwgL8gB13f-VeEGg_QYaGsk1ktlK8tmDrDlKkAsmjrsoS8B1GU67HoRhkWKzwcoJ4EV6LgylFwCZGTyMoqVjdHko2rf7-4mF_8728dTzpRxhk_lLf6mZC3czPMVdyAMZ3vd9gnVwqMoLizjwZEp0SmEvJyVLN5XFi5iAPCT4jaU8C5A9YK32_p2ibUDEd2KC6y13cP_Yg8yhC2hMykY3Kw3ez8CYCurX0TZtYv16ExqA
  priority: 102
  providerName: ProQuest
Title Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
URI http://ard.bmj.com/content/76/4/654.full
https://www.ncbi.nlm.nih.gov/pubmed/28073800
https://www.proquest.com/docview/1882905453
https://www.proquest.com/docview/1857751043
https://www.proquest.com/docview/1881757427
https://pubmed.ncbi.nlm.nih.gov/PMC5530342
Volume 76
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9UwEB72AuKLeN_qeojgmxRO2jRJH9dll0U4i8iuHJ9K06S0sqc9nAu4v8c_6kx60aOy6lPbNG1DZ5L5kszMB_CGx4mlrCWhLBMViijXobFahojt0V46J5Wl9Y7Zpby4Fu_nyXwP-J938Hns6VhWldsubL1GkXJ8DYUeiH049JlZSKk_X_0YfDXXA0meSKXqXbrueBGlA9ao6NoHuZnFl10L9Rvs_NV78idzdP4QHvQ4kp10gn8Ee655DPdm_U75E_g2erlV9ZL13ljMfV22tCTINi3bbHHWv2KNo2bUa9Yx77C6qWpT01kXmnXL8sYyWpH37KP-Cq2pI9I71pZscYvWkLTsBiuV2G3oo3jK-oyta0ZLvcz_E5zg15ahslY-ldJTuD4_uzq9CHtChtAQ70EYR6mTMpWlls5STKxLTanKPJVYkBQ8nyrHY2GNzXmirbZTW2gjisIZE2NB_AwOmrZxR8Byh8BhqoyVUSmUKw0OdDlXeYGARRsbBfAWRZEtu5QbmZ-qxD58epBhRjLMOhkGIAeRZUWf25woNm7-_uB0fPCfv3U86ETW9_d1xjVtSCMajQN4Pd7GnkrbL3nj2i3VSZTCIVDcWUcjnlMiUgE879RsbNegpQGoHQUcK1Cm8N07TV35jOHEDRWL6MV__dSXcD8iDOPdlI7hYLPauleIwDZmAvtqria-503g8OR0NvuEx3dnlx8-fgdKxTTO
linkProvider BMJ Publishing Group Ltd
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcKp5lSwEjwQlFbGLH9h4Q4tFqS7srhFqptxDHjjaomyzdrGB_D3d-IzN5lQWpcOnNSZzE8oxnxp7HB_DM56GlqiWeTEPliSDWnrFaemjbo750TipL5x3jiRydiA-n4ekG_GxzYSisspWJlaC2RUJn5C99TS4_1Pf89fyrR6hR5F1tITRqtjh0q2-4ZVu8OniP9H0eBPt7x-9GXoMq4Bkq3u_xYOikHMpUS2cpsdMNTarSeCjxRpj48UA5nwtrbOyH2mo7sIk2IkmcMRxvcPzuNdgUHLcyPdh8uzf5-OlC9mtftxh9YihVE1Hm8wpW5nzqljObLZA1fZwOSqEQqNPM7Mu6VvzL1P0zYvM3Fbh_C7Ya25W9qZntNmy4_A5cHzfe-bvwo4usm2Zz1kSAMfd9XtAxJCsLVi5n-BGWOxpGtmA12g_L8mlmMmrV6WArFueWkRegQjytrlCDOwLaY0XKZivUwMTZZ9gpRZrQT7HJmiqxC0bHy6yaiLgsMstwgUyr8k334ORKyHUfenmRuwfAYofGykAZK4NUKJcaFK6xr-IEjSRtbNCHF0iKaF6X-Yiq7RGvUrZbwkVEuKgmXB9kS7IoaeqpE6zH2b9fHHQv_ve_dlueiBoZs4guVkQfnnaPUTqQyyfOXbGkPqFSKHbFpX002pBKBKoP2zWbdeOiWkkc9xR9UGsM2HWg6uTrT_JsWlUpJzwqLoKdy4f-BG6MjsdH0dHB5PAh3AzIaKrionahV54v3SM0-UrzuFlnDD5f9dL-BUbwcW0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFLZKkSouqKwNLWAkOKGo4zixnQNCiDJqKa04UGluIY4dJaiTDE1GML-Hf8Gv4z1nKQNS4dJbFiex8lb7LR8hzxmPDHYt8UUeST8MUuVro4QPvj3YS2uFNLjfcXIqDs_C97NotkF-DrUwmFY56ESnqE2d4R75PlMY8gN7z_fzPi3i48H09eKrjwhSGGkd4DQ6Fjm2q2-wfGteHR0ArV8EwfTdp7eHfo8w4Gts5O_zILZCxCJXwhos8rSxzmWexgIuRBlLJ9IyHhptUhYpo8zEZEqHWWa15nCBw3tvkJuSRwxlTM7kpRVQTA1ofWEsZJ9bxrgDmLko7HJuygaYlMGPwWKKEKybnn9Zt49_Ob1_5m7-Zgyn2-R278XSNx3b3SEbtrpLtk76OP098mPMsSvKBe1zwaj9vqhxQ5K2NW2Xc3gJrSxOo2xoh_tDy6oodYlHXWHYiqaVoRgPcNin7gxsuUXIPVrndL4CW4w8fg6DcqAIfhQOad8vtqG40Uzdj0jbujQURKVwjZzuk7NrIdYDslnVld0hNLXgtkykNiLIQ2lzDWo2ZTLNwF1S2gQeeQmkSBZdw4_ELZS4K94eCJcg4ZKOcB4RA8mSrO-sjgAf5_9-cDI--N_f2ht4Ium1TZNcyoZHno23QU9g8CetbL3EMZGUoIDDK8co8CZlGEiPPOzYbJwXdk3isLrwiFxjwHEA9ilfv1OVhetXjshUPAweXT31p2QLBDr5cHR6vEtuBeg9uQSpPbLZXiztY_D9Wv3ECRkln69bqn8B6Ol0PQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+exposure+to+tumour+necrosis+factor+inhibitor+therapy+and+incidence+and+severity+of+myocardial+infarction+in+patients+with+rheumatoid+arthritis&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Low%2C+Audrey+S+L&rft.au=Symmons%2C+Deborah+P+M&rft.au=Lunt%2C+Mark&rft.au=Mercer%2C+Louise+K&rft.series=Extended+report&rft.date=2017-04-01&rft.pub=BMJ+Publishing+Group&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=76&rft.issue=4&rft.spage=654&rft.epage=660&rft_id=info:doi/10.1136%2Fannrheumdis-2016-209784&rft_id=info%3Apmid%2F28073800&rft.externalDocID=PMC5530342
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon